UNIQURE
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commi... ssion in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
UNIQURE
Industry:
Biotechnology Genetics Health Care Medical
Founded:
1998-01-01
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.uniqure.com
Total Employee:
501+
Status:
Active
Contact:
+31 20 566 7394
Email Addresses:
[email protected]
Total Funding:
780.74 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Analytics Google Maps Content Delivery Network SSL By Default Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
AMSilk
AMSilk produces and distributes high-quality silk biopolymers.
CasZyme
CasZyme is a biotech firm that is involved in research & development of cas proteins and CRISPR based molecular tools.
CimCure
CimCure focuses on design and development of a novel class of active cancer immunotherapies.
LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp.
Nuclidium
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Whitehead Institute for Biomedical Research
Whitehead Institute is a research institution for human health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2021-06-23 | Corlieve Therapeutics | Corlieve Therapeutics acquired by UniQure | 46.3 M EUR |
2014-08-12 | InoCard | InoCard acquired by UniQure | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - UniQure
Forbion Capital Partners
Forbion Capital Partners investment in Private Equity Round - UniQure
Chiesi Farmaceutici
Chiesi Farmaceutici investment in Private Equity Round - UniQure
Coller Capital
Coller Capital investment in Private Equity Round - UniQure
Official Site Inspections
http://www.uniqure.com Semrush global rank: 7.01 M Semrush visits lastest month: 936
- Host name: 104.17.124.41
- IP address: 104.17.124.41
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "UniQure"
UniQure - Crunchbase Company Profile & Funding
UniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and …See details»
Working at uniQure | Culture & Careers
Working together across the organization, we can achieve far more, faster, than even the most talented individual. When we collaborate together, we grow together. Innovate every day. Breakthrough innovation comes from …See details»
uniQure - The Org
UniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly …See details»
uniQure - LinkedIn
UniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a ...See details»
uniQure - Overview, News & Similar companies | ZoomInfo.com
Aug 6, 2024 uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 …See details»
uniQure N.V. - AnnualReports.com
UniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly advance a pipeline of proprietary gene …See details»
uniQure - LinkedIn
UniQure | 22,684 followers on LinkedIn. Transforming the lives of patients through gene therapy | uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic …See details»
uniQure Company Profile - Office Locations, Competitors, …
Sep 16, 2024 uniQure has 5 employees across 5 locations and $15.84 m in annual revenue in FY 2023. See insights on uniQure including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
uniQure - businessabc.net
Nov 20, 2024 uniQure. uniQure # 7525 Rank $ 284.83M Marketcap . Netherlands. Country . Leadership team. Mr. Matthew Craig Kapusta (CEO & Exec. Director) Mr. Christian Klemt …See details»
uniQure | A Global Leader in Gene Therapy
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease; May 7, 2024 uniQure …See details»
uniQure N.V. (QURE) Company Profile & Overview - Stock Analysis
Jun 20, 2007 uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial …See details»
UniQure - Funding, Financials, Valuation & Investors - Crunchbase
UniQure is registered under the ticker NASDAQ:QURE . Their stock opened with $29.50 in its Feb 6, 2014 IPO. UniQure is funded by 4 investors. Hercules Capital and Forbion Capital Partners …See details»
Our Leadership | Pioneers & Leaders - uniQure
For most of his career, Dr. Gut worked at Novo Nordisk Inc. (NYSE: NVO), where he headed the company’s U.S. Biopharm Medical organization with leading products in hemophilia, …See details»
uniQure Announces Strategic Reorganization to Reduce Operating …
Oct 5, 2023 --uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a strategic reorganization …See details»
Corporate Governance | Investors & Media - uniQure
UniQure Stock Ownership Guidelines PDF; More on Investors & Media. Press Releases Events & Presentations Shareholder Info uniQure. uniQure N.V. Paasheuvelweg 25a, 1105 BP …See details»
uniQure: gene therapy pioneer to biotech rebuff?
Nov 16, 2023 Meanwhile, uniQure’s gene therapy focus was expanding to other indications as well. Its treatment for lipoprotein lipase deficiency (LPLD), Glybera, became the first gene …See details»
uniQure Announces Third Quarter 2024 Financial Results and
Nov 5, 2024 The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field ...See details»
uniQure Announces Third Quarter 2024 Financial Results
Nov 5, 2024 In July 2024, uniQure announced positive interim data from the ongoing U.S. and European Phase I/II studies of AMT-130 for the treatment of early-stage Huntington’s disease 1. At 24 months, the ...See details»
3 biotechs try to beat the summer heat by shedding staff - Fierce …
Aug 1, 2024 The restructure is expected to be complete in the fourth quarter of this year and slash recurring costs by 40%, or $75 million annually. As of June 30, UniQure had $524 million …See details»
uniQure (QURE) Earnings Date and Reports 2025 - MarketBeat
Nov 29, 2024 uniQure announced Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.91, which beat analysts' consensus estimates of -$1.12 by $0.21. Quarterly revenue was …See details»